

**AmeriChoice Pharmacy & Therapeutics Committee Minutes**

**June 10, 2010**


**Meeting Date:** June 10, 2010

**Location:** Via conference call

**Members in Attendance:**

**Members Absent:**

**Guests:**



Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
Meeting called to order		5:10 PM		
I. Minutes of previous meetings	R. Brekosky	Minutes of March 2010 AMC P&T meeting were reviewed	Minutes reviewed, approved	14:0
II. New Formulations	A. Hindman	1) Pennsaid (diclofenac sodium topical solution)  Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Zegerid OTC (omeprazole/sodium bicarbonate)  Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	3) Mirapex ER (pramipexole extended release)  Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	4) Exalgo (hydromorphone extended release)  Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	5) Zirgan (ganciclovir ophthalmic solution)  Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	6) Rymed (dexchlorpheniramine/phenylephrine)  Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	7) Ed Chlortan (chlorpheniramine)  Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	14:0
	L. Cormier	8) Norvir tablets (ritonavir)  Recommendation: Categorize as Essential Drug, add as preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
III. Class Reviews and New Drug Reviews	A. Hindman	1) Incretin Mimetics  Recommendation: Confirm class review	Motion made, seconded, and carried to accept recommendation	14:0
		1a) Victoza (liraglutide)  Recommendation: Categorize as Optional Inclusion, add as preferred with PA on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Nebulized Antibiotics	Motion made, seconded, and carried to accept recommendation	14:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
		Recommendation: Categorize as Essential Class, add TOBI as preferred through specialty pharmacy on the Medicaid PDLs		

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
III. Class Reviews and New Drug Reviews CONT'D		2a) Cayston (aztreonam)  Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	3) Multiple Sclerosis  Recommendation: Confirm class review	Motion made, seconded, and carried to accept recommendation	14:0
	D. Morgan	3a) Ampyra (dalfampridine)  Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
IV. PDL Additions/Modifications	J. Bellicini	1) Tamsulosin  Recommendation: Add tamsulosin as preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	J. Bellicini	2) Sensipar  Recommendation: Add Sensipar as preferred with PA on the Unison legacy Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	J. Bellicini	3) Percocet Age Edit  Recommendation: Remove Percocet age edit on all Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	J. Bellicini	4) Ondansetron Quantity Limit  Recommendation: Increase the quantity limit to 30 tablets per fill and 90 tablets per month on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
	J. Bellicini	5) Leflunomide  Recommendation: Remove leflunomide prior authorization requirement on all Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	15:0
V. Clinical Guidelines - Pharmacy	A. Hindman	1) Xifaxan	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	2) Lidoderm	Motion made, seconded, and carried to accept recommendation	14:1
	A. Hindman	3) Zetia	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	4) Topical NSAIDs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	5) Ampyra	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	6) Angiotensin Receptor Blockers	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	7) Non-preferred Drugs	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	8) Multaq	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	9) Sensipar	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	10) Oral Chemotherapy	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	11) Celebrex	Motion made, seconded, and carried to accept recommendation	15:0
	A. Hindman	12) Isulin Pens/Cartridges	Motion made, seconded, and carried to accept recommendation	15:0
	D. Morgan	13) Interferon/Ribavirin	Motion made, seconded, and carried to accept recommendation	15:0
VI. Quality Monitoring	R. Brekosky	1) The Quality Management Reports for the 1st quarter of 2010 were reviewed	Motion made, seconded, and carried to accept recommendation	15:0
	L. Cormier	2) The Concurrent and Retrospective DUR Reports for the 1st quarter of 2010 were reviewed		
	J. Bellicini	3) Top 25 drugs by cost and volume for the 1st quarter of 2010 were reviewed		
	J. Bellicini	4) Top 10 drugs requested - approvals and denials for the 1st quarter 2010 were reviewed		
	J. Bellicini	5) The grievance and appeals statistics for the 1st quarter of 2010 were reviewed		
	J. Bellicini	6) The pharmacist IRR results for the 2nd quarter of 2010 were reviewed		
Adjournment			6:35 PM	

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
-------------	---------	------------	-----------------------------	---------------

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
-------------	---------	------------	-----------------------------	---------------

Votes not totaling 15 are the result of abstentions.

***NOTE: Actions documented in these minutes document what transpired at the meeting and do not serve as notice of formulary/PDL change. All formulary/PDL changes must be approved by the Department of Public Welfare. Formulary/PDL changes are only official once approved and subsequently posted/distributed in a change notice.***